Serum neuron-specific enolase: a new tool for seizure risk monitoring after status epilepticus

Background and purpose There is a need for accurate biomarkers to monitor electroencephalography (EEG) activity and assess seizure risk in patients with acute brain injury. Seizure recurrence may lead to cellular alterations and subsequent neurological sequelae. Whether neuron-specific enolase (NSE) and S100-beta (S100B), brain injury biomarkers, can reflect EEG activity and help to evaluate the seizure risk was investigated. Methods Eleven patients, admitted to an intensive care unit for refractory status epilepticus, who underwent a minimum of 3 days of continuous EEG concomitantly with daily serum NSE and S100B assays were included. At 103 days the relationships between serum NSE and S100B levels and two EEG scores able to monitor the seizure risk were investigated. Biochemical biomarker thresholds able to predict seizure recurrence were sought. Results Only NSE levels positively correlated with EEG scores. Similar temporal dynamics were observed for the time courses of EEG scores and NSE levels. NSE levels above 17 ng/ml were associated with seizure in 71% of patients. An increase of more than 15% of NSE levels was associated with seizure recurrence in 80% of patients. Conclusions Our study highlights the potential of NSE as a biomarker of EEG activity and to assess the risk of seizure recurrence.

Automated summary

The study discussed the relationship between neuron-specific enolase (NSE) and S100-beta (S100B) levels with EEG activity to evaluate seizure risk in patients with acute brain injury. It was found that NSE levels were positively correlated with EEG scores, and higher NSE levels were associated with an increased risk of seizure recurrence.